Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 35008821)

  • 21. Design, synthesis, and Structure-Activity Relationships (SAR) of 3-vinylindazole derivatives as new selective tropomyosin receptor kinases (Trk) inhibitors.
    Duan Y; Wang J; Zhu S; Tu ZC; Zhang Z; Chan S; Ding K
    Eur J Med Chem; 2020 Oct; 203():112552. PubMed ID: 32702585
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Entrectinib: First Global Approval.
    Al-Salama ZT; Keam SJ
    Drugs; 2019 Sep; 79(13):1477-1483. PubMed ID: 31372957
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activity of Entrectinib in a Patient With the First Reported
    Sigal D; Tartar M; Xavier M; Bao F; Foley P; Luo D; Christiansen J; Hornby Z; Maneval EC; Multani P
    J Natl Compr Canc Netw; 2017 Nov; 15(11):1317-1322. PubMed ID: 29118225
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).
    Drilon A; Siena S; Ou SI; Patel M; Ahn MJ; Lee J; Bauer TM; Farago AF; Wheler JJ; Liu SV; Doebele R; Giannetta L; Cerea G; Marrapese G; Schirru M; Amatu A; Bencardino K; Palmeri L; Sartore-Bianchi A; Vanzulli A; Cresta S; Damian S; Duca M; Ardini E; Li G; Christiansen J; Kowalski K; Johnson AD; Patel R; Luo D; Chow-Maneval E; Hornby Z; Multani PS; Shaw AT; De Braud FG
    Cancer Discov; 2017 Apr; 7(4):400-409. PubMed ID: 28183697
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancer.
    Ku BM; Bae YH; Lee KY; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Invest New Drugs; 2020 Apr; 38(2):360-368. PubMed ID: 31124056
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mechanisms of Entrectinib Resistance in a Neuroblastoma Xenograft Model.
    MacFarland SP; Naraparaju K; Iyer R; Guan P; Kolla V; Hu Y; Tan K; Brodeur GM
    Mol Cancer Ther; 2020 Mar; 19(3):920-926. PubMed ID: 31871269
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antitumor Activity of Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor, in
    Smith KM; Fagan PC; Pomari E; Germano G; Frasson C; Walsh C; Silverman I; Bonvini P; Li G
    Mol Cancer Ther; 2018 Feb; 17(2):455-463. PubMed ID: 29237803
    [TBL] [Abstract][Full Text] [Related]  

  • 28. NTRK oncogenic fusions are exclusively associated with the serrated neoplasia pathway in the colorectum and begin to occur in sessile serrated lesions.
    Kim JH; Hong JH; Choi YL; Lee JA; Seo MK; Lee MS; An SB; Sung MJ; Cho NY; Kim SS; Shin YK; Kim S; Kang GH
    J Pathol; 2021 Dec; 255(4):399-411. PubMed ID: 34402529
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Entrectinib for the treatment of metastatic NSCLC: safety and efficacy.
    Sartore-Bianchi A; Pizzutilo EG; Marrapese G; Tosi F; Cerea G; Siena S
    Expert Rev Anticancer Ther; 2020 May; 20(5):333-341. PubMed ID: 32223357
    [No Abstract]   [Full Text] [Related]  

  • 30. Overexpression of NCAPG inhibits cardia adenocarcinoma apoptosis and promotes epithelial-mesenchymal transition through the Wnt/β-catenin signaling pathway.
    Zhang X; Zhu M; Wang H; Song Z; Zhan D; Cao W; Han Y; Jia J
    Gene; 2021 Jan; 766():145163. PubMed ID: 32980450
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Frequent amplification of PTP1B is associated with poor survival of gastric cancer patients.
    Wang N; She J; Liu W; Shi J; Yang Q; Shi B; Hou P
    Cell Cycle; 2015; 14(5):732-43. PubMed ID: 25590580
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combating autophagy is a strategy to increase cytotoxic effects of novel ALK inhibitor entrectinib in neuroblastoma cells.
    Aveic S; Pantile M; Seydel A; Esposito MR; Zanon C; Li G; Tonini GP
    Oncotarget; 2016 Feb; 7(5):5646-63. PubMed ID: 26735175
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HER3 PET Imaging Predicts Response to Pan Receptor Tyrosine Kinase Inhibition Therapy in Gastric Cancer.
    Esfahani SA; de Aguiar Ferreira C; Rotile NJ; Ataeinia B; Krishna S; Catalano OA; Caravan P; Yen YF; Heidari P; Mahmood U
    Mol Imaging Biol; 2023 Apr; 25(2):353-362. PubMed ID: 35962301
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting of SPP1 by microRNA-340 inhibits gastric cancer cell epithelial-mesenchymal transition through inhibition of the PI3K/AKT signaling pathway.
    Song SZ; Lin S; Liu JN; Zhang MB; Du YT; Zhang DD; Xu WH; Wang HB
    J Cell Physiol; 2019 Aug; 234(10):18587-18601. PubMed ID: 30953349
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tropomyosin receptor kinase inhibitors: an updated patent review for 2016-2019.
    Bailey JJ; Jaworski C; Tung D; Wängler C; Wängler B; Schirrmacher R
    Expert Opin Ther Pat; 2020 May; 30(5):325-339. PubMed ID: 32129124
    [No Abstract]   [Full Text] [Related]  

  • 36. Entrectinib and other ALK/TRK inhibitors for the treatment of neuroblastoma.
    Pacenta HL; Macy ME
    Drug Des Devel Ther; 2018; 12():3549-3561. PubMed ID: 30425456
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adenovirus-mediated TIPE2 overexpression inhibits gastric cancer metastasis via reversal of epithelial-mesenchymal transition.
    Yin H; Huang X; Tao M; Hu Q; Qiu J; Chen W; Wu J; Xie Y
    Cancer Gene Ther; 2017 Apr; 24(4):180-188. PubMed ID: 28186089
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Suppression of BMX-ARHGAP fusion gene inhibits epithelial-mesenchymal transition in gastric cancer cells via RhoA-mediated blockade of JAK/STAT axis.
    Xu XF; Wang JJ; Ding L; Ye JS; Huang LJ; Tao L; Gao F; Ji Y
    J Cell Biochem; 2019 Jan; 120(1):439-451. PubMed ID: 30216523
    [TBL] [Abstract][Full Text] [Related]  

  • 39. INC280 inhibits Wnt/β-catenin and EMT signaling pathways and its induce apoptosis in diffuse gastric cancer positive for c-MET amplification.
    Sohn SH; Kim B; Sul HJ; Kim YJ; Kim HS; Kim H; Seo JB; Koh Y; Zang DY
    BMC Res Notes; 2019 Mar; 12(1):125. PubMed ID: 30871613
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications.
    Ardini E; Menichincheri M; Banfi P; Bosotti R; De Ponti C; Pulci R; Ballinari D; Ciomei M; Texido G; Degrassi A; Avanzi N; Amboldi N; Saccardo MB; Casero D; Orsini P; Bandiera T; Mologni L; Anderson D; Wei G; Harris J; Vernier JM; Li G; Felder E; Donati D; Isacchi A; Pesenti E; Magnaghi P; Galvani A
    Mol Cancer Ther; 2016 Apr; 15(4):628-39. PubMed ID: 26939704
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.